A Phase 1 Study of AJ1-11095 in People With Myelofibrosis

Full Title

A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Purpose

Researchers want to find the best dose of AJ1-11095 to treat myelofibrosis. The people in this study have myelofibrosis that came back or got worse after treatment.

AJ1-11095 works by blocking JAK proteins. When JAK proteins send too many signals, the body makes the wrong amount of blood cells. By blocking these proteins, AJ1-11095 may slow JAK signaling and help your body make the right amount of blood cells. AJ1-11095 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have either myelofibrosis that developed on its own or as a complication of polycythemia vera or essential thrombocythemia.
• Have myelofibrosis that came back or keeps growing after treatment.
• Be age 18 or older.
• You may join this study even if you need help taking care of yourself. You may also join even if you are in a bed or chair for more than half the time you’re awake.

Contact

For more information and to see if you can join this study, please call Dr. Raajit Rampal’s office at 646-608-3746.